Bharat Biotech Ltd.'s COVID-19 vaccine has an overall efficacy rate of 77.8% when it comes to preventing symptomatic disease, according to a new study published Thursday in The Lancet. The findings are from a Phase 3 clinical trial conducted in India that had more than 25,000 adult participants; they are in line with the company's previous statements about the vaccine's efficacy rate. The research also found that Covaxin has an efficacy rate of 93.4% at preventing severe disease. The privately held company, which jointly developed the vaccine with the Indian Council of Medical Research, has said Covaxin has been administered to more than 100 million adults worldwide. It is not authorized in the U.S. Ocugen Inc. (OCGN), which has commercialization rights to the vaccine in the U.S., said last week that it has asked the Food and Drug Administration to authorize Covaxin in children between the ages of 2 and 18 years old.
(END) Dow Jones Newswires
11-12-21 1025ETCopyright (c) 2021 Dow Jones & Company, Inc.